Eli Lilly and Co (BSP:LILY34)
R$ 130.52 -2.2 (-1.66%) Market Cap: 3.72 Til Enterprise Value: 3.84 Til PE Ratio: 113.84 PB Ratio: 56.38 GF Score: 73/100

Eli Lilly and Co at Evercore ISI HealthCONx Conference Transcript

Nov 28, 2023 / 08:50PM GMT
Release Date Price: R$95.8 (-1.15%)
Umer Raffat
Evercore ISI Institutional Equities, Research Division - Senior MD & Senior Analyst of Equity Research

(technical difficulty)

for being here. Pleasure to have management team from Eli Lilly. There's a ton to go through. But Dan, I'll turn it over to you on what's on top of your mind, and we'll jump right into it.

Daniel M. Skovronsky
Eli Lilly and Company - EVP, Chief Scientific Officer and President of Lilly Research Laboratories & Lilly immunology

Yes. No. Thanks for hosting us here. It's been a great meeting so far, and nice to have this opportunity to talk at a fireside. I guess probably most people are excited about Lilly because of what we're doing in obesity and Alzheimer's disease. But just a reminder that we have a great business in immunology with a couple of new products being planned to launch.

We're also doing great things in oncology with Verzenio as a huge product and Jaypirca, which is in the early stages of launching across indications. So really a very diversified pharmaceutical company even though I

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot